InMed granted first PCT patent in Mexico for novel cannabinoid analog compounds

InMed Pharmaceuticals Inc.

Patent No. 417531 issued in Mexico; covers novel small molecule compounds and methods of preparation.
Therapeutic applications include pain, glaucoma, inflammatory disease, anxiety, and neurological conditions like Parkinson's and Alzheimer's.
Patent holds 20-year term; international application pending in U.S., Europe, Japan, and others.
InMed now has 14 patent families covering compositions, formulations, manufacturing, and methods of use.
Compounds are drug candidates for Alzheimer's disease and dry age-related macular degeneration programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.